

Global Allergy Immunotherapy (AIT) Market: Industry Analysis & Outlook

(2019-2023)

March 2019



Executive Summary

Allergy Immunotherapy (AIT), also known as desensitization, is a treatment option for environmental allergies and asthma. It is aimed to induce the natural regulation of the immune system through complex mechanisms. AIT involves exposing people to larger amounts of allergen in an attempt to change the immune system's response towards them.

AIT can be administered by SCIT or SLIT. SCIT is the more common route for administration. It holds a major share in the global AIT market. Currently, the market is dominated by SCIT formulations marketed under named patient product (NPP).


The global AIT market is expected to grow at a lucrative growth rate in the near future. The market would witness growth due to numerous factors such as increasing demand for existing treatments, mainly for desensitization to allergens such as house dust mites and grass pollen; a shift in the market, driven by the regulatory authorities, in favor of registered products, which are progressively replacing NPPs; and the arrival on the market of new treatments with MA.

Geographically, Europe dominates the AIT market due to the high concentration of key companies in the region, European countries are taking initiatives to reduce the use of NPP and increasing prevalence of allergy. However, in terms of patients volume receiving AIT, the U.S. dominates the market.

The global AIT market is highly consolidated in nature. Key players of the market include ALK-Abello; Stallergenes Greer; Allergy Therapeutics; and Allergopharma (Merck Group). All the players are highly focused on developing new therapeutics for allergy indications. Allergy Therapeutics' Pollinex Quattro Grass, an allergy vaccine marketed in Europe as an NPP, is one of the most advanced competitors.


Global allergy immunotherapy market is likely to grow with increasing prevalence of allergy, progressing drug pipeline, urbanization and lifestyle changes...

Global Allergy Immunotherapy Market Value Forecast (2019-2023)




- Global allergy immunotherapy market is expected to reach US\$.. billion in the year 2023, increasing from US\$.. billion in 2019, at a CAGR of ..%.
- SCIT formulations held a lion share in the global allergy immunotherapy market value in 2018.
- Europe made up a major share of the global allergy immunotherapy market value in 2018.

Global Allergy Immunotherapy Market by Administration Route (2018)




Global Allergy Immunotherapy Market by Region (2018)




European allergy immunotherapy market is likely to grow due to shifting regulatory landscape towards registered products from NPPS, increasing demand for allergy treatments, favorable patient base...

Europe Allergy Immunotherapy Market Value Forecast (2018-2023)




- European allergy immunotherapy market is expected to reach US\$.. billion in 2018, increasing from US\$.. billion in the year 2018, at a CAGR of ..%.
- The U.S. allergy immunotherapy market value is expected to reach US\$.. million in 2023, increasing from US\$.. million in 2018.
- Allergy immunotherapy market is expected to reach US\$.. million in 2023, increasing from US\$.. million in 2018, in rest of the world, at a CAGR of ..%.

The U.S. Allergy Immunotherapy Market Value Forecast (2018-2023)



ROW Allergy Immunotherapy Market Value Forecast (2018-2023)



Disclaimer

This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create other works from this report or use them in any way for commercial purpose without our prior permission. Further, you cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased the corporate license of this report.

We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.

Koncept Analytics
CS-36, First Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T: +91-120-4130959
M: +91-9811715635
vikas@konceptanalytics.com

www.konceptanalytics.com